Navigation Links
Moffitt Cancer Center researchers find potential target for treating metastatic cancer
Date:12/13/2011

TAMPA, Fla. (Dec. 13, 2011) Finding ways to counteract or disrupt the invasive nature of cancer cells, called "metastasis," has been a long-term goal of cancer researchers. Now, researchers at Moffitt Cancer Center in Tampa, Fla., have identified an interactive pathway that regulates metastases in some cancers that may be vulnerable to chemical targeting in order to prevent cancer cell proliferation and tumor growth.

Ongoing collaboration by researchers in Moffitt's Departments of Tumor Biology and Drug Discovery has revealed the potential for combating metastatic disease by disrupting the interaction between the retinoblastoma tumor suppressor protein (Rb) and Raf-1 (a gene with a potential to cause cancer) with RRD-251, a selective, chemical disrupter of Rb-Raf-1 interaction.

Their recent study, aimed at understanding the association between Rb-Raf-1 and genes known to be over-expressed in metastatic non-small lung cancer, was published in the recent issue of Cancer Research, a journal of the American Association for Cancer Research. This work, using a mouse model, was a continuation of the researchers' study of RRD-251's successful disruption of Rb-Raf-1 interaction in metastatic melanoma in test mice, a study published in Molecular Cancer Therapeutics in 2010.

"The Rb gene is mutated in a variety of cancers," said study corresponding author Srikumar P. Chellappan, Ph.D., chair of Moffitt's Department of Tumor Biology and scientific director of the National Functional Genomics Center. "Our earlier studies have shown that Raf-1 interacts with Rb early in the cell cycle and facilitates its inactivation."

The ongoing work of Chellappan and his colleagues in Moffitt's Department of Tumor Biology focuses on understanding the mechanisms by which external signals regulate cell proliferation and how a loss of regulation may cause cancer. They work extensively with the Rb protein, the Raf-1 signaling molecule, and E2Fs, genes that affect cell proliferation, differentiation and cell death (apoptosis).

E2Fs, a family of genes that play a role in the mammalian cell cycle and can transform normal cells to have properties of cancer cells, interact with Rb. In addition, E2Fs are important for the development, differentiation and DNA damage repair programs in cells. Their previous studies have shown that RRD-251-mediated disruption of the Rb-Raf-1 interaction could inhibit the activity of E2F. They now show that E2Fs regulate matrix metalloproteinases (MMPs), which are involved in cancer metastasis, and RRD-251 can prevent the expression of MMPs.

"A considerable amount of research has been dedicated to identifying novel E2F- regulated genes, but a clear role for E2Fs in cancer progression and metastasis had not been established," explained Chellappan. "We find that the Rb-E2F pathway contributes to the expression of many genes involved in different aspects of cancer, and that targeting this pathway might fight metastatic disease."

Their study found that a mouse model of non small cell lung cancer metastasis being treated with RRD-251 had "significantly less metastasis to the lung and surrounding areas." They concluded that disrupting the Rb-Raf-1 interaction using RRD-251 could inhibit the regulatory function of E2Fs as an activator of gene promoters that are related to tumor growth and metastases.

"There is a possibility that E2F might indirectly regulate tumor metastasis as a consequence of its activating these genes," suggested Chellappan. "Taken together, our studies link the Rb-E2F cell cycle regulatory pathway to advanced stages of cancer development and metastasis."

Although further studies are underway, their work suggests that disrupting Rb-Raf-1 interaction can prevent cancer cell proliferation, cell vascular growth (angiogenesis), tumor growth, and the metastatic colonization of organs.

"This approach appears to be a fruitful avenue to combat metastatic disease," concluded Chellappan.


'/>"/>

Contact: Ferdie De Vega
Ferdinand.DeVega@moffitt.org
813-745-7858
H. Lee Moffitt Cancer Center & Research Institute
Source:Eurekalert

Related medicine news :

1. Moffitt researchers will be strong participants in American Society of Hematology meeting
2. Moffitt Cancer Center researchers find MK1775 active against sarcomas
3. Moffitt Cancer Center researchers find men less willing to be screened for cancer
4. Moffitt Cancer Center researchers unravel biochemical factor important in tumor metastasis
5. Moffitt Cancer Center researchers find regulatory T-cell clue to help prevent GVHD
6. Moffitt Cancer Center researchers find more clues to causes of breast cancer
7. Moffitt researchers find possible key to preventing chemotherapy resistance in ovarian cancer
8. Moffitt Cancer Center researchers use new tool to counter multiple myeloma drug resistance
9. Moffitt Cancer Center and GLG Pharma LLC sign licensing agreement to develop the next generation of targeted anti-cancer therapeutics
10. Moffitt Cancer Center and GLG Pharma, LLC sign licensing agreement to develop the next generation of targeted anti-cancer therapeutics
11. Birth Defects Seem Rare in Kids of Childhood Cancer Survivors
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/27/2017)... (PRWEB) , ... February 27, 2017 , ... Elisa Guajardo Carothers is not your typical ... to studying to become a nun. Now, she writes about God, when she isn’t swimming ... Know BC and AD, Here is BS! (Before Satan),” she offers a comedic look at ...
(Date:2/27/2017)... N. Y. (PRWEB) , ... February 27, 2017 , ... ... ( ILADS ) has disclosed that despite scientific studies, the Center for Disease Control ... chronic Lyme disease . Kenneth B. Liegner, M.D. has compiled into a ...
(Date:2/27/2017)... ... February 27, 2017 , ... Silicon Valley Hair Institute, a ... an upgrade to the company's Yelp listing. Bay Area residents struggling from thinning ... as Platelet Rich Plasma (PRP) therapy, hair transplantation techniques such as Follicular Unit ...
(Date:2/26/2017)... ... February 26, 2017 , ... This is an extension of ... to be ISO/IEC 17025:2005 INAB accredited for Der p 1 (house dust mite ... globally recognised standard that sets out requirements for the technical competence of testing ...
(Date:2/26/2017)... (PRWEB) , ... February 26, ... ... sets a new technology standard in staffing, scheduling, and reporting for healthcare ... and predict activity throughout the entire staffing process. StaffBridge technology improves staffing ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... Research and Markets has announced the addition of the "Hemophilia ... ... Drugs Price Analysis and Strategies - 2016, provides drug pricing data and ... questions: What are the key drugs marketed ... Global Hemophilia market? What are the unit prices and ...
(Date:2/24/2017)... , Feb. 24, 2017 Juan ... & Associates PC , a boutique securities firm headquartered ... York City , announces that a class action ... Massachusetts  against Inotek Pharmaceuticals Corporation (NASDAQ: ... the Company,s securities between July 23, 2015 and December 30, ...
(Date:2/24/2017)... Feb. 23, 2017  Directors from Pharma To Market Pty Ltd ... joined forces, resulting in the founding of Pharma To Market Pte ... To Market are pleased to announce their expansion into ... Singapore . The company are delighted to appoint ... the Singapore based entity. Joelle brings with ...
Breaking Medicine Technology: